Cure One, Cure Many Award
The American Brain Foundation’s Cure One, Cure Many Award seeks to attract the best minds in brain disease research to advance research that addresses key knowledge gaps that cut across brain diseases. The award brings together funders to advance progress on large-scale, cross-cutting research topics.
The specific priority areas for this award are announced periodically.
Improving Diagnosis for Lewy Body Dementia
In partnership with the Alzheimer’s Association, The Michael J. Fox Foundation for Parkinson’s Research, and the American Academy of Neurology, the American Brain Foundation is seeking to accelerate progress in the diagnosis of Lewy body dementia (LBD). LBD is the most common form of dementia after Alzheimer’s disease.
Recipients of the 2022 Cure One, Cure Many Award for the early diagnosis of Lewy body dementia: Owen A. Ross, PhD, Pamela J. McLean, PhD, and Bradley F. Boeve, MD from Mayo Clinic have assembled a team with the major goal of driving the development and validation of a blood-based biomarker to identify overt and prodromal dementia with Lewy bodies.
They have taken a multipronged approach to support the diagnosis of Lewy body dementia by employing protein biomarkers, extracellular vesicles, and seed aggregation assays. Investigators at Mayo Clinic are joined by colleagues at the University of Pennsylvania (Dr. David Issadore) and the University of North Texas Health Science Center (Dr. Sid O’Bryant). The data generated will be combined with a vast amount of clinical, imaging, and pathologic data available to the investigators, and machine learning approaches will be used to create a unified diagnostic model.
Watch the webinar
2022 Cure One Cure Many Award Event
The American Brain Foundation held an event to announce the recipients of the 2022 Cure One, Cure Many Award for the early diagnosis of Lewy body dementia: Owen A. Ross, PhD, Pamela J. McLean, PhD, and Bradley F. Boeve, MD from Mayo Clinic. The major goal of the assembled team is to drive the development and validation of a blood-based biomarker to identify overt and prodromal dementia with Lewy bodies.
